Elicio Therapeutics Inc
ELTX8.195USD
+0.255+3.21%
交易中 （美东）报价延迟15分钟
141.43M总市值
亏损市盈率 TTM
关于 Elicio Therapeutics Inc 公司
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a pipeline of immunotherapies for the treatment of cancer. The Company provides a platform, amphiphile (AMP) that delivers immunotherapeutics directly to the lymph nodes (brain center) of the immune system. The Company’s clinical and preclinical pipeline includes the lymph node targeted therapeutic cancer vaccines ELI-002, which is being evaluated in a Phase II study, designed to stimulate an immune response against mutant kirsten rat sarcoma (KRAS). Its ELI-007 is being evaluated in a preclinical study for the treatment of mutant v-raf murine sarcoma viral oncogene homolog B1 (BRAF) driven cancers, and ELI-008, is being evaluated in a preclinical study for use in the treatment of mutated tumor protein p53 (TP53) expressing cancers.
Elicio Therapeutics Inc简介
公司代码ELTX
公司名称Elicio Therapeutics Inc
上市日期Feb 05, 2021
CEOConnelly (Robert)
员工数量32
证券类型Ordinary Share
年结日Feb 05
公司地址451 D Street, 5Th Floor
城市BOSTON
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编02459
电话18572090050
网址https://elicio.com/
公司代码ELTX
上市日期Feb 05, 2021
CEOConnelly (Robert)
Elicio Therapeutics Inc公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Jay R. Venkatesan, M.D.
Dr. Jay R. Venkatesan, M.D.
Director
Director
170.22K
-5.71%
Ms. Yekaterina (Katie) Chudnovsky, J.D.
Ms. Yekaterina (Katie) Chudnovsky, J.D.
Independent Director
Independent Director
12.72K
--
Ms. Karen J. Wilson, CPA
Ms. Karen J. Wilson, CPA
Independent Director
Independent Director
1.87K
--
Dr. Peter Demuth, Ph.D.
Dr. Peter Demuth, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
743.00
+95.01%
Dr. Julian Adams, Ph.D.
Dr. Julian Adams, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Christopher M. (Chris) Haqq, M.D., Ph.D.
Dr. Christopher M. (Chris) Haqq, M.D., Ph.D.
Executive Vice President, Head - Research and Development, Chief Medical Officer
Executive Vice President, Head - Research and Development, Chief Medical Officer
--
--
Ms. Carol Ashe
Ms. Carol Ashe
Independent Director
Independent Director
--
--
Dr. Allen R. Nissenson, M.D.
Dr. Allen R. Nissenson, M.D.
Independent Director
Independent Director
--
--
Dr. Robert R. Ruffolo, Jr.
Dr. Robert R. Ruffolo, Jr.
Independent Director
Independent Director
--
--
Mr. Robert (Bob) Connelly
Mr. Robert (Bob) Connelly
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Jay R. Venkatesan, M.D.
Dr. Jay R. Venkatesan, M.D.
Director
Director
170.22K
-5.71%
Ms. Yekaterina (Katie) Chudnovsky, J.D.
Ms. Yekaterina (Katie) Chudnovsky, J.D.
Independent Director
Independent Director
12.72K
--
Ms. Karen J. Wilson, CPA
Ms. Karen J. Wilson, CPA
Independent Director
Independent Director
1.87K
--
Dr. Peter Demuth, Ph.D.
Dr. Peter Demuth, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
743.00
+95.01%
Dr. Julian Adams, Ph.D.
Dr. Julian Adams, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Christopher M. (Chris) Haqq, M.D., Ph.D.
Dr. Christopher M. (Chris) Haqq, M.D., Ph.D.
Executive Vice President, Head - Research and Development, Chief Medical Officer
Executive Vice President, Head - Research and Development, Chief Medical Officer
--
--
收入明细
由于公司未披露，未能获取相关数据
由于公司未披露，未能获取相关数据
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 11月23日 周日
更新时间: 11月23日 周日
持股股东
股东类型
持股股东
持股股东
占比
GKCC, LLC
30.97%
Knoll Capital Management, LLC
3.61%
Clal Biotechnology Industries Ltd
2.75%
The Vanguard Group, Inc.
2.71%
Actyus Private Equity SGIIC, S.A.
1.54%
其他
58.42%
持股股东
持股股东
占比
GKCC, LLC
30.97%
Knoll Capital Management, LLC
3.61%
Clal Biotechnology Industries Ltd
2.75%
The Vanguard Group, Inc.
2.71%
Actyus Private Equity SGIIC, S.A.
1.54%
其他
58.42%
股东类型
持股股东
占比
Corporation
32.50%
Hedge Fund
4.86%
Investment Advisor
4.52%
Holding Company
2.75%
Investment Advisor/Hedge Fund
2.25%
Individual Investor
1.51%
Research Firm
0.18%
其他
51.42%
机构持股
更新时间: 12月8日 周一
更新时间: 12月8日 周一
报告期
机构数
持股数
持股占比
持股变动
2025Q4
58
2.05M
11.00%
--
2025Q3
59
2.05M
11.96%
+477.65K
2025Q2
52
1.58M
11.53%
-116.12K
2025Q1
59
1.67M
8.91%
+250.74K
2024Q4
54
504.27K
8.35%
-37.38K
2024Q3
58
541.64K
9.80%
-115.54K
2024Q2
70
657.30K
8.80%
+242.22K
2024Q1
96
415.08K
8.40%
-443.93K
2023Q4
102
540.87K
10.06%
+911.00
2023Q3
115
547.56K
11.25%
+45.29K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
GKCC, LLC
5.42M
33.15%
--
--
Jun 03, 2025
Knoll Capital Management, LLC
630.91K
3.86%
--
--
Jun 30, 2025
Clal Biotechnology Industries Ltd
481.73K
2.95%
-52.31K
-9.80%
Apr 09, 2024
The Vanguard Group, Inc.
454.62K
2.78%
+132.93K
+41.32%
Jun 30, 2025
Actyus Private Equity SGIIC, S.A.
856.38K
5.24%
+268.56K
+45.69%
Mar 31, 2025
Venkatesan (Jay R)
170.22K
1.04%
-10.31K
-5.71%
Mar 24, 2025
Geode Capital Management, L.L.C.
120.83K
0.74%
+43.36K
+55.98%
Jun 30, 2025
Susquehanna International Group, LLP
17.02K
0.1%
-14.34K
-45.72%
Jun 30, 2025
查看更多
持股ETF
更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
iShares Micro-Cap ETF
0.02%
iShares Micro-Cap ETF
占比0.02%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Jun 01, 2023
Merger
10→1
Jun 01, 2023
Merger
10→1
Jun 01, 2023
Merger
10→1
Jun 01, 2023
Merger
10→1
公告日期
类型
比率
Jun 01, 2023
Merger
10→1
Jun 01, 2023
Merger
10→1
Jun 01, 2023
Merger
10→1
Jun 01, 2023
Merger
10→1
常见问题
Elicio Therapeutics Inc的前五大股东是谁？
Elicio Therapeutics Inc 的前五大股东如下：
GKCC, LLC持有股份：5.42M，占总股份比例：33.15%。
Knoll Capital Management, LLC持有股份：630.91K，占总股份比例：3.86%。
Clal Biotechnology Industries Ltd持有股份：481.73K，占总股份比例：2.95%。
The Vanguard Group, Inc.持有股份：454.62K，占总股份比例：2.78%。
Actyus Private Equity SGIIC, S.A.持有股份：856.38K，占总股份比例：5.24%。
GKCC, LLC持有股份：5.42M，占总股份比例：33.15%。
Knoll Capital Management, LLC持有股份：630.91K，占总股份比例：3.86%。
Clal Biotechnology Industries Ltd持有股份：481.73K，占总股份比例：2.95%。
The Vanguard Group, Inc.持有股份：454.62K，占总股份比例：2.78%。
Actyus Private Equity SGIIC, S.A.持有股份：856.38K，占总股份比例：5.24%。
Elicio Therapeutics Inc的前三大股东类型是什么？
Elicio Therapeutics Inc 的前三大股东类型分别是：
GKCC, LLC
Knoll Capital Management, LLC
Clal Biotechnology Industries Ltd
GKCC, LLC
Knoll Capital Management, LLC
Clal Biotechnology Industries Ltd
有多少机构持有Elicio Therapeutics Inc(ELTX)的股份？
截至2025Q4，共有58家机构持有Elicio Therapeutics Inc的股份，合计持有的股份价值约为2.05M，占公司总股份的11.00%。与2025Q3相比，机构持股有所增加，增幅为-0.96%。
哪个业务部门对Elicio Therapeutics Inc的收入贡献最大？
在--，--业务部门对Elicio Therapeutics Inc的收入贡献最大，创收--，占总收入的--%。
